New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment
Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients. The results revealed two genes that could help physicians make more informed treatment decisions for patients with this disease.